Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 167 in Healthy Men and Postmenopausal Women.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs AMG 167 (Primary) ; AMG 167 (Primary)
- Indications Metabolic bone diseases; Osteoporosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 06 Mar 2010 Actual end date (November 2009) added as reported by ClinicalTrials.gov.
- 06 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.